These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22258256)

  • 41. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
    Angelova A; Rommelaere J
    Viruses; 2019 May; 11(5):. PubMed ID: 31060205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
    Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
    Viruses; 2021 May; 13(6):. PubMed ID: 34071585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An in-frame deletion in the NS protein-coding sequence of parvovirus H-1PV efficiently stimulates export and infectivity of progeny virions.
    Weiss N; Stroh-Dege A; Rommelaere J; Dinsart C; Salomé N
    J Virol; 2012 Jul; 86(14):7554-64. PubMed ID: 22553326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.
    Marr M; D'Abramo A; Pittman N; Agbandje-McKenna M; Cotmore SF; Tattersall P
    Viruses; 2018 Jan; 10(2):. PubMed ID: 29385689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protoparvovirus Cell Entry.
    Ros C; Bayat N; Wolfisberg R; Almendral JM
    Viruses; 2017 Oct; 9(11):. PubMed ID: 29072600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Viral genes as oncolytic agents for cancer therapy.
    Gupta SK; Gandham RK; Sahoo AP; Tiwari AK
    Cell Mol Life Sci; 2015 Mar; 72(6):1073-94. PubMed ID: 25408521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
    Ammayappan A; Peng KW; Russell SJ
    J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Examination and Reconstruction of Three Ancient Endogenous Parvovirus Capsid Protein Gene Remnants Found in Rodent Genomes.
    Callaway HM; Subramanian S; Urbina CA; Barnard KN; Dick RA; Bator CM; Hafenstein SL; Gifford RJ; Parrish CR
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis.
    Lavie M; Struyf S; Stroh-Dege A; Rommelaere J; Van Damme J; Dinsart C
    Virology; 2013 Dec; 447(1-2):221-32. PubMed ID: 24210118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.
    Paglino JC; Ozduman K; van den Pol AN
    J Virol; 2012 Jul; 86(13):7280-91. PubMed ID: 22553327
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
    Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viral oncolysis that targets Raf-1 signaling control of nuclear transport.
    Riolobos L; Valle N; Hernando E; Maroto B; Kann M; Almendral JM
    J Virol; 2010 Feb; 84(4):2090-9. PubMed ID: 19939915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis.
    Bär S; Rommelaere J; Nüesch JP
    PLoS Pathog; 2015 Mar; 11(3):e1004703. PubMed ID: 25742010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
    Bhat R; Dempe S; Dinsart C; Rommelaere J
    Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concepts to Reveal Parvovirus-Nucleus Interactions.
    Mattola S; Hakanen S; Salminen S; Aho V; Mäntylä E; Ihalainen TO; Kann M; Vihinen-Ranta M
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
    Frehtman V; Wohlfarth D; Müller M; Krebs O; Leuchs B
    Appl Microbiol Biotechnol; 2023 Aug; 107(15):4777-4787. PubMed ID: 37209160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
    Akladios C; Aprahamian M
    Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
    Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.